COMP <GO>
VFC vs TMO // ALTMAN Z-SCORE & DEBT/EQUITY
V.F. Corporation (NYSE) VS. Thermo Fisher Scientific Inc (NYSE) • 15-METRIC TALLY: VFC 8
— TMO 6
▲ ALTMAN Z-SCORE & DEBT/EQUITY LEADER: TMO
LAST: $18.30 (-0.16%) • MKT CAP: $7.22B
balance-sheet
1.70
LAST: $697.00 (-1.72%) • MKT CAP: $262.22B
balance-sheet
4.50
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (VFC VS. TMO)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | VFC | TMO | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 54.80% | 41.00% | +13.80 | VFC | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 11.50% | 9.30% | +2.20 | VFC | /roic <GO> |
| EV/EBITDA & P/E Valuation | 9.9x | 30.4x | -20.50 | VFC | /valuation <GO> |
| Free Cash Flow Yield | 3.31% | 2.40% | +0.91 | VFC | /fcf-yield <GO> |
| Operating Margin | 6.00% | 17.40% | -11.40 | TMO | /operating-margins <GO> |
| Net Profit Margin | 2.70% | 15.10% | -12.40 | TMO | /net-margins <GO> |
| Revenue Growth (YoY) | 1.10% | 3.90% | -2.80 | TMO | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 1.95% | 0.24% | +1.71 | VFC | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity ACTIVE | 1.70 | 4.50 | -2.80 | TMO | /balance-sheet <GO> |
| Piotroski F-Score Quality | 7/9 | 8/9 | -1.00 | TMO | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | 6.70% | 6.70% | 0.00 | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 75.8 | 59.1 | +16.66 | VFC | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 0.95 | 0.94 | +0.01 | VFC | /macro-sensitivity <GO> |
| Forward P/E Multiple | 26.3x | 36.3x | -10.00 | VFC | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $7.22B | $262.22B | -$255.00B | TMO | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | VFC REV | TMO REV | VFC GROSS % | TMO GROSS % | VFC FCF | TMO FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $9.61B | $44.56B | 54.8% | 44.0% | $239.0M | $6.29B |
| FY 2024 | $9.50B | $42.88B | 53.5% | 44.0% | $37.5M | $7.27B |
| FY 2023 | $9.92B | $42.86B | 44.0% | 44.0% | $568.4M | $6.48B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
VFC // BETA 0.95
TMO // BETA 0.94